A Case of Catatonia and Neuroleptic Malignant Syndrome Probably Associated with Antipsychotic in Korea

Overview

Journal Psychiatry Investig

Specialty Psychiatry

Date 2011 Aug 20

PMID 21852996

Citations 2

Authors

Ho-Dong Choi

Kyoung-Keun Kim

Bon-Hoon Koo

Affiliations

Soon will be listed here.

Abstract

Several studies have reported on catatonia caused by the use of antipsychotic drugs and on the association between catatonia and neuroleptic malignant syndrome (NMS), but none has reported such a case in Korea. Here, we report the case of a 20-year-old woman whose catatonia and NMS appeared associated with the administration of an atypical antipsychotic drug. We discuss the association between NMS and catatonia due to neuroleptic use.

Citing Articles

A Neuroleptic Malignant Syndrome Without Rigidity.

Ozdemir I, Kuru E, Safak Y, Tulaci R Psychiatry Investig. 2018; 15(2):226-229.

PMID: 29475219 PMC: 5900391. DOI: 10.30773/pi.2017.06.05.

Delirium followed by neuroleptic malignant syndrome in rehabilitation setting. Is it anger reaction before discharge?.

Al Owesie R, Robert A Pan Afr Med J. 2013; 15:26.

PMID: 24009802 PMC: 3758850. DOI: 10.11604/pamj.2013.15.26.2218.

References

Paparrigopoulos T, Tzavellas E, Ferentinos P, Mourikis I, Liappas J . Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry. 2009; 10(1):70-3. DOI: 10.1080/15622970701287369. View

Chakraborty N, Johnston T . Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol. 2004; 19(6):351-3. DOI: 10.1097/00004850-200411000-00007. View

Malur C, Pasol E, Francis A . ECT for prolonged catatonia. J ECT. 2001; 17(1):55-9. DOI: 10.1097/00124509-200103000-00012. View

Caroff S, Mann S . Neuroleptic malignant syndrome. Med Clin North Am. 1993; 77(1):185-202. DOI: 10.1016/s0025-7125(16)30278-4. View

White D, Robins A . Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry. 1991; 158:419-21. DOI: 10.1192/bjp.158.3.419. View

Northoff G, Pfennig A, Krug M, Danos P, Leschinger A, Schwarz A . Delayed onset of late movement-related cortical potentials and abnormal response to lorazepam in catatonia. Schizophr Res. 2000; 44(3):193-211. DOI: 10.1016/s0920-9964(99)00189-9. View

Tsai J, Yang P, Yen J, Chen C, Yang M . Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy. 2005; 25(8):1156-9. DOI: 10.1592/phco.2005.25.8.1156. View

Zalsman G, Lewis R, Konas S, Loebstein O, Goldberg P, Burguillo F . Atypical neuroleptic malignant syndrome associated with risperidone treatment in two adolescents. Int J Adolesc Med Health. 2004; 16(2):179-82. DOI: 10.1515/ijamh.2004.16.2.179. View

Carroll B, Lee J . Catatonia is a risk factor for neuroleptic malignant syndrome. J Clin Psychiatry. 2005; 65(12):1722-3. DOI: 10.4088/jcp.v65n1219d. View

10.

Fink M . Neuroleptic malignant syndrome and catatonia: one entity or two?. Biol Psychiatry. 1996; 39(1):1-4. DOI: 10.1016/0006-3223(95)00552-8. View

11.

Northoff G, Wenke J, Pflug B . Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psychol Med. 1996; 26(3):547-53. DOI: 10.1017/s0033291700035625. View

12.

Addonizio G, Susman V, Roth S . Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry. 1987; 22(8):1004-20. DOI: 10.1016/0006-3223(87)90010-2. View

13.

Carroll B, Taylor R . The nondichotomy between lethal catatonia and neuroleptic malignant syndrome. J Clin Psychopharmacol. 1997; 17(3):235-8. DOI: 10.1097/00004714-199706000-00026. View

14.

Peralta V, Cuesta M, Serrano J, Mata I . The Kahlbaum syndrome: a study of its clinical validity, nosological status, and relationship with schizophrenia and mood disorder. Compr Psychiatry. 1997; 38(1):61-7. DOI: 10.1016/s0010-440x(97)90055-9. View

15.

Norgard N, Stark J . Olanzapine-associated neuroleptic malignant syndrome. Pharmacotherapy. 2006; 26(8):1180-2. DOI: 10.1592/phco.26.8.1180. View

16.

Northoff G . What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis. Behav Brain Sci. 2003; 25(5):555-77; discussion 578-604. DOI: 10.1017/s0140525x02000109. View

17.

Koch M, Chandragiri S, Rizvi S, Petrides G, Francis A . Catatonic signs in neuroleptic malignant syndrome. Compr Psychiatry. 2000; 41(1):73-5. DOI: 10.1016/s0010-440x(00)90135-4. View

18.

Mathews T, Aderibigbe Y . Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol. 2001; 2(2):129-144. DOI: 10.1017/S1461145799001388. View

19.

Lew T, Tollefson G . Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry. 1983; 18(12):1441-6. View

20.

Leibold J, Patel V, Hasan R . Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther. 2004; 26(7):1105-8. DOI: 10.1016/s0149-2918(04)90182-8. View